E2F1 and breast carcinoma: Overexpression of several genes is known to drive centrosome amplification; a gene expression-based signature called the CA20 signature, which computes the sum of the normalized (log2 median-centered) expression levels of the 20 centrosome structural genes and genes whose dysregulation induces CA (AURKA, CCNA2, CCND1, CCNE1, CDK1, CEP63, CEP152, E2F1, E2F2, LMO4, MDM2, MYCN, NDRG1, NEK2, PIN1, PLK1, PLK4, SASS6, STIL, TUBG1), was found to have a strong prognostic value in breast cancer [18].